Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978775 | 0.92 | CHRM1 (0.65) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14964864 | 0.92 | CHRM1 (0.65) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14978767 | 0.92 | CHRM1 (0.65) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14978900 | 0.91 | CHRM1 (0.53) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14978902 | 0.91 | CHRM1 (0.53) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14978888 | 0.88 | CHRM1 (0.62) | CHRM1CHRM2TP53TDP1GAA | |
| SCHEMBL14964766 | 0.86 | CHRM1 (0.53) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14978777 | 0.85 | CHRM1 (0.52) | CHRM1CHRM2TP53TDP1CHRM4 | |
| SCHEMBL14978809 | 0.85 | CHRM1 (0.50) | CHRM1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL16210266 | 0.85 | CHRM1 (0.50) | CHRM1KMT2ALMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10413553-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180153900-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180153900-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-9907805-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9907805-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9573929-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-21 | — | — | US | disclosed |
| US-9573929-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-21 | — | — | US | disclosed |
| EP-2780015-B1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-01-04 | — | — | EP | disclosed |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | NXERA PHARMA UK LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | NXERA PHARMA UK LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-20180153900-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-10973832-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-10413553-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CHRM2 2/4885TP53 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.